Brokerages Anticipate Intersect ENT, Inc. (NASDAQ:XENT) to Announce -$0.42 EPS

Equities analysts expect Intersect ENT, Inc. (NASDAQ:XENT) to post ($0.42) earnings per share for the current quarter, according to Zacks Investment Research. Four analysts have made estimates for Intersect ENT’s earnings, with the highest EPS estimate coming in at ($0.36) and the lowest estimate coming in at ($0.46). Intersect ENT reported earnings of ($0.34) per share during the same quarter last year, which suggests a negative year over year growth rate of 23.5%. The business is expected to report its next quarterly earnings report on Monday, November 1st.

On average, analysts expect that Intersect ENT will report full-year earnings of ($1.81) per share for the current year, with EPS estimates ranging from ($1.89) to ($1.75). For the next fiscal year, analysts forecast that the firm will post earnings of ($1.23) per share, with EPS estimates ranging from ($1.34) to ($1.11). Zacks’ EPS calculations are an average based on a survey of sell-side research analysts that follow Intersect ENT.

Intersect ENT (NASDAQ:XENT) last released its quarterly earnings data on Friday, August 6th. The medical equipment provider reported ($0.49) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.42) by ($0.07). The firm had revenue of $27.30 million for the quarter, compared to analysts’ expectations of $27.77 million. Intersect ENT had a negative return on equity of 102.23% and a negative net margin of 66.55%. Intersect ENT’s revenue for the quarter was up 178.6% on a year-over-year basis. During the same period last year, the firm posted ($0.65) earnings per share.

XENT has been the subject of several recent analyst reports. BTIG Research cut shares of Intersect ENT from a “buy” rating to a “neutral” rating in a research report on Tuesday, August 10th. SVB Leerink cut shares of Intersect ENT from an “outperform” rating to a “market perform” rating and set a $28.25 price target for the company. in a research report on Wednesday, August 11th. Canaccord Genuity cut shares of Intersect ENT from a “buy” rating to a “hold” rating and reduced their price target for the company from $29.00 to $28.25 in a research report on Friday, August 6th. Zacks Investment Research lowered shares of Intersect ENT from a “hold” rating to a “sell” rating and set a $19.00 price objective on the stock. in a research note on Tuesday, May 18th. Finally, Guggenheim lowered shares of Intersect ENT from a “buy” rating to a “neutral” rating and set a $28.30 price objective on the stock. in a research note on Monday, August 9th. One equities research analyst has rated the stock with a sell rating and six have issued a hold rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $25.40.

A number of institutional investors and hedge funds have recently modified their holdings of the business. Landscape Capital Management L.L.C. grew its position in Intersect ENT by 2.3% during the second quarter. Landscape Capital Management L.L.C. now owns 24,226 shares of the medical equipment provider’s stock worth $414,000 after buying an additional 545 shares during the period. Royal Bank of Canada lifted its holdings in shares of Intersect ENT by 6.8% in the second quarter. Royal Bank of Canada now owns 8,780 shares of the medical equipment provider’s stock valued at $150,000 after purchasing an additional 558 shares in the last quarter. The Manufacturers Life Insurance Company lifted its holdings in shares of Intersect ENT by 4.4% in the second quarter. The Manufacturers Life Insurance Company now owns 20,142 shares of the medical equipment provider’s stock valued at $344,000 after purchasing an additional 844 shares in the last quarter. Swiss National Bank lifted its holdings in shares of Intersect ENT by 1.4% in the first quarter. Swiss National Bank now owns 67,300 shares of the medical equipment provider’s stock valued at $1,405,000 after purchasing an additional 900 shares in the last quarter. Finally, Weiss Multi Strategy Advisers LLC lifted its holdings in shares of Intersect ENT by 3.7% in the second quarter. Weiss Multi Strategy Advisers LLC now owns 40,174 shares of the medical equipment provider’s stock valued at $687,000 after purchasing an additional 1,439 shares in the last quarter. Institutional investors own 87.04% of the company’s stock.

Shares of Intersect ENT stock traded up $0.15 during trading on Wednesday, hitting $27.35. 13,782 shares of the stock were exchanged, compared to its average volume of 416,982. The stock has a market cap of $911.17 million, a price-to-earnings ratio of -13.08 and a beta of 1.63. The firm’s 50-day moving average price is $24.56 and its 200 day moving average price is $21.22. Intersect ENT has a 12-month low of $14.68 and a 12-month high of $28.17. The company has a debt-to-equity ratio of 1.53, a current ratio of 2.03 and a quick ratio of 1.70.

Intersect ENT Company Profile

Intersect ENT, Inc is a commercial drug delivery company, which engages in the treatment of ear, nose, and throat conditions. Its products include PROPEL and SINUVA. The PROPEL used to maintain the opening and locally deliver steroid after sinus surgery. The SINUVA is used to treat adult patients with ethmoid sinus surgery yet suffer from recurrent sinus obstruction due to polyps.

Further Reading: What is the Stochastic Momentum Index (SMI)?

Get a free copy of the Zacks research report on Intersect ENT (XENT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Intersect ENT (NASDAQ:XENT)

Receive News & Ratings for Intersect ENT Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intersect ENT and related companies with MarketBeat.com's FREE daily email newsletter.